Health & Medical · Week of Nov 2, 2026
Q3 earnings bring guidance raises and FDA, DEA milestones
Third-quarter 2026 earnings dominated the week, with Waters and Caris raising guidance, GRAIL awaiting an FDA decision and Trulieve reporting DEA registrations.
Third-quarter 2026 results made up most of the week's health and medical releases. Waters Corporation, Caris Life Sciences and Evolent Health each raised some portion of full-year guidance: Waters lifted total reported revenue guidance by $43 million at the midpoint, Caris raised its revenue range to $1.04 to $1.05 billion, and Evolent raised its Adjusted EBITDA outlook while reiterating revenue guidance. Smaller companies also reported improved bottom lines, with Trulieve and Syra Health both swinging to net income from prior-year losses.
Regulatory milestones ran alongside the numbers. GRAIL said an FDA advisory panel voted in favor of its Galleri test, with a decision anticipated by early Q1 2027, and Trulieve said it received final DEA registrations for state licensed medical marijuana dispensaries. Syra Health and DarioHealth both cited CMS programs in their releases, and Dario named John R. Palumbo chairman of its board.
Evolent Health, Inc.
Evolent Announces Third Quarter 2026 Results
Evolent Health reported third quarter 2026 revenue of $725.4 million, up from $479.5 million a year earlier, and a net loss attributable to common shareholders of $23.6 million, while its medical expense ratio rose to 93.0% from 85.0%. The company reiterated 2026 revenue guidance of $2.6 billion to $2.7 billion, raised Adjusted EBITDA guidance to $130.0 million to $135.0 million and says it renewed its largest Surgical Management customer contract for four years.
Waters Corporation
Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results
Waters Corporation reported third quarter 2026 revenue of $1.767 billion, including $896 million from the acquired Biosciences and Diagnostic Solutions businesses, and adjusted EPS of $4.10, up 21%. The company raised full-year 2026 guidance to total reported revenue of $6.479 billion to $6.497 billion and announced it has acquired MOBILion Systems, Inc., a developer of SLIM high-resolution ion mobility separation technology.
Trulieve Cannabis Corp.
Trulieve Reports Third Quarter 2026 Results
Trulieve reported third quarter 2026 revenue of $230 million, down 20% from $288 million a year earlier, and net income attributable to common shareholders of $1 million, with results reflecting only medical operations after the June 3, 2026 deconsolidation of Harvest operations. The company says it received final DEA registrations for state licensed medical marijuana dispensaries under the Controlled Substances Act and repaid $65 million of mortgage notes ahead of their 2028 maturity.
Caris Life Sciences
Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Caris Life Sciences reported third-quarter 2026 revenue of $275.4 million, up 27% year over year, on approximately 61,500 clinical cases, and net income of $15.3 million. The company raised full-year 2026 revenue guidance to $1.04 to $1.05 billion and says growth came mainly from higher clinical case volume and average selling price improvements in molecular profiling.
GRAIL, Inc.
GRAIL Reports Third Quarter 2026 Financial Results
GRAIL reported third quarter 2026 total revenue of $37.5 million, Galleri test volume of more than 56,000 tests, and a net loss of $103.6 million, with $788.7 million in cash, cash equivalents and short-term marketable securities. The company says an FDA advisory panel voted in favor of approving its Galleri multi-cancer early detection test in September and anticipates an FDA decision by early Q1 2027; the release states the test has not been cleared or approved by the FDA.
Community Healthcare Trust Incorporated
Community Healthcare Trust Announces Results for the Three Months Ended September 30, 2026
Community Healthcare Trust reported third quarter 2026 net income of about $3.1 million, or $0.09 per diluted share, and FFO of $0.54 per diluted share, and declared an unchanged quarterly dividend of $0.33 per share payable November 25, 2026. The company says it has completed $32.3 million in property dispositions since the close of the second quarter and has four properties under definitive purchase agreements for about $99.0 million.
Syra Health
Syra Health Delivers Third Consecutive Profitable Quarter: Record Revenue of $2.6 Million, Up 52%, and 46.3% Gross Margin
Syra Health reported third-quarter 2026 revenue of $2,557,295, up 52%, and net income of $344,610, which it says marks its third consecutive profitable quarter. Following CMS approval of Syrenity for the ACCESS Model, the company says it is recruiting Accountable Care Organizations to use the product with partner HealthSync.
DarioHealth Corp.
Dario Names Veteran Healthcare Executive John R. Palumbo Chairman of the Board as Company Positions Itself to Lead the Convergence of Consumer and Payer-Funded Care
DarioHealth appointed John R. Palumbo, a board member since April 2026, as Chairman effective November 3, 2026, succeeding Yoav Shaked, who will remain a director. The company says the change comes as consumer-directed and payer-funded healthcare converge, and that Palumbo will join its November 12, 2026 earnings call.
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not Today Parents reporting.